Eisai Co., Ltd. Logo

Eisai Co., Ltd.

A global, research-based pharmaceutical firm that develops and markets prescription and OTC drugs.

4523 | T

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
Japan
Address:
文京区小石川4丁目6番10号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Eisai Co., Ltd. is a global, research-based pharmaceutical company founded in 1941. It is engaged in the discovery, development, manufacturing, and marketing of pharmaceutical products, with a portfolio that includes prescription medicines and over-the-counter drugs. The company operates under its core "human health care" (hhc) philosophy, which prioritizes patients and their families to enhance the benefits provided by healthcare. A key corporate initiative involves improving access to medicines for people in developing and emerging countries, exemplified by its program to supply treatments for lymphatic filariasis.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-04 07:00
Regulatory News Service
訂正報告書(大量保有報告書・変更報告書)
Japanese 46.9 KB
2025-06-19 09:25
Post-Annual General Meeting Information
臨時報告書
Japanese 31.9 KB
2025-06-13 04:30
Governance Information
内部統制報告書-第113期(2024/04/01-2025/03/31)
Japanese 25.1 KB
2025-06-13 04:29
Registration Form
確認書
Japanese 8.1 KB
2025-06-13 04:28
Annual Report
有価証券報告書-第113期(2024/04/01-2025/03/31)
Japanese 5.2 MB
2025-06-03 08:00
Major Shareholding Notification
変更報告書
Japanese 39.0 KB
2025-05-13 08:00
Major Shareholding Notification
大量保有報告書
Japanese 37.9 KB
2025-05-08 09:00
Regulatory News Service
公開買付報告書
Japanese 41.0 KB
2025-04-01 08:00
M&A Activity
訂正公開買付届出書
Japanese 177.2 KB
2025-03-17 06:00
M&A Activity
公開買付届出書
Japanese 348.4 KB
2025-03-12 07:06
Board/Management Information
臨時報告書
Japanese 21.8 KB
2024-12-11 02:14
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 23.2 KB
2024-11-15 02:00
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 21.7 KB
2024-11-08 06:17
Regulatory News Service
確認書
Japanese 8.0 KB
2024-11-08 06:16
Interim Report
半期報告書-第113期(2024/04/01-2025/03/31)
Japanese 268.5 KB

Automate Your Workflow. Get a real-time feed of all Eisai Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Eisai Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
ChoA Pharmaceutical Co., LTD. Logo
Global manufacturer of OTC medicines and health supplements distributed through pharmacies.
South Korea 034940
CHUGAI PHARMACEUTICAL CO., LTD. Logo
An R&D pharma leader in Japan creating innovative drugs via antibody engineering technology.
Japan 4519
Cinclus Pharma Holding AB Logo
Clinical-stage pharma developing a next-gen P-CAB drug for severe GERD patients.
Sweden CINPHA
Circio Holding ASA Logo
Developing circular RNA vector tech and immunotherapies for gene and cell therapies.
Norway CRNA
CJ Bioscience Logo
Develops microbiome therapeutics for oncology & IBD using an AI drug discovery platform.
South Korea 311690
CKD Bio Corp. Logo
Develops and manufactures probiotics & APIs using fermentation, also offering cGMP CMO services.
South Korea 063160
CMG Pharmaceutical Co., Ltd. Logo
Develops and manufactures prescription drugs, specializing in Oral Thin Film (OTF) technology.
South Korea 058820
co.don AG Logo
Develops personalized cartilage cell transplants for minimally invasive joint repair.
Germany CNW
Compugen Ltd. Logo
Uses AI to discover and develop novel antibody immunotherapies for hard-to-treat cancers.
Israel CGEN
CORESTEMCHEMON Inc. Logo
Develops stem cell therapies & provides preclinical CRO services to pharma & biotech.
South Korea 166480

Talk to a Data Expert

Have a question? We'll get back to you promptly.